3,4-dihydro-4,4-dimethyl-6-acetyl-naphthalen-1(2H)-one | 150932-00-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 3,4-dihydro-4,4-dimethyl-6-acetyl-naphthalen-1(2H)-one
• 英文别名: 3,4-dihydro-4,4-dimethyl-6-acetyl-1(2H)-naphthalenone；6-acetyl-4,4-dimethyl-2,3-dihydronaphthalen-1-one
• CAS: 150932-00-6
• 化学式: C₁₄H₁₆O₂
• 分子量: 216.28
• InChiKey: UHQWDMQZOWNOTO-UHFFFAOYSA-N

物化性质

• 沸点：
  362.2±41.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-4,4-dimethyl-6-acetyl-naphthalen-1(2H)-one 在 盐酸 、 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 16.08h， 生成 1-(8,8-Dimethyl-7,8-dihydro-naphthalen-2-yl)-ethanone
  参考文献：
  名称：

  α-四氢萘酮选择性转化为二氢萘

  摘要：

  描述了将α-四氢萘酮选择性转化为二氢萘的简单程序。提出了一种新型的质子酸催化氢化物迁移机理。

  DOI：

  10.1016/0040-4039(96)00309-7
• 作为产物：
  描述：

  4,4-二甲基-3,4-二氢-2H-萘-1-酮 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 、 水 为溶剂， 25.0 ℃ 、413.69 kPa 条件下， 反应 5.0h， 生成 3,4-dihydro-4,4-dimethyl-6-acetyl-naphthalen-1(2H)-one
  参考文献：
  名称：

  Protein tyrosine kinase inhibitory properties of planar polycyclics obtained from the marine sponge Xestospongia cf. carbonaria and from total synthesis

  摘要：

  Nine related polycyclic quinones and hydroquinones of the halenaquinone class were isolated from two Indo-Pacific collections of the sponge Xestospongia cf. carbonaria. The halenaquinone family appears not to be of polyketide origin but can be biogenetically derived by the union of a sesquiterpene and a quinone. Four new metabolites were characterized including tetrahydrohalenaquinone B (8a), 14-methoxyhalenaquinone (9), xestoquinolide A (10), and xestoquinolide B (11). These were accompanied by five known compounds, halenaquinone (3), halenaquinol (4), halenaquinol sulfate (5), xestoquinone (6), and tetrahydrohalenaquinone A (7a). The new structures were established from 2D NMR data, and the absolute stereochemistry of the chiral centers in 7 and 8 was determined by the formation of 7b and 7c, the bis esters of O-methylmandelic acid. A series of polycyclic models of natural products 3 and 6 were synthesized and included 16-23. The more complex members of this group were assembled via a 4 + 2 cycloaddition between an o-quinodimethane and a functionalized enone. The marine natural products plus two known fungal metabolites, viridin (13) and wortmannin (14), along with halenaquinone synthetic model compounds, were each tested for their ability to inhibit the activity of pp60v-src protein tyrosine kinase (PTK). Halenaquinone and 14-methoxyhalenaquinone were the most potent with IC50 values <10 muM. The other compounds were either less potent or inactive, and a rationalization for this SAR (structure activity relationship) pattern is presented.

  DOI：

  10.1021/jo00070a023

文献信息

• Oxime substituted tetrahydronaphthalene derivatives having retinoid
  申请人：Allergan

  公开号：US05723666A1

  公开（公告）日：1998-03-03

  Compounds of the formula ##STR1## have retinoid-like or retinoid antagonist-like biological activity.

  ##STR1##的化合物具有类似视黄醇或视黄醇拮抗剂的生物活性。
• O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
  申请人：Allergan Sales, Inc.

  公开号：US06344561B2

  公开（公告）日：2002-02-05

  Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

  式中符号的含义如申请中所述，具有类视黄醇或类视黄醇拮抗剂样的生物活性。
• [EN] SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSES DE THIOPHENE CARBOXAMIDE SUBSTITUES UTILISES POUR TRAITER UNE INFLAMMATION
  申请人：PHARMACIA CORP

  公开号：WO2004009582A1

  公开（公告）日：2004-01-29

  The present invention provides substituted thiophene carboxamide compounds having structural Formula I and isomers, tautomers, polymorphs, carriers, prodrugs, and pharmaceutically acceptable salts thereof, compositions comprising such, and methods for treating diseases associated with kinase activity. More specifically, the present invention provides methods of treatment of a variety of diseases associated with IKK2 including the treatment of inflammation, other inflammation-associated disorders, such as, as an analgesic in the treatment of pain and headaches, arthritis, including but not limited to rheumatoid arthritis, asthma, gastrointestinal conditions such as inflammatory bowel disease, vascular diseases, viral infections such as AIDS, and cancer.

  本发明提供具有结构式I的取代噻吩羧酰胺化合物及其异构体、互变异构体、多晶型、载体、前药和其药学上可接受的盐，包含这些化合物的组合物，以及治疗与激酶活性相关疾病的方法。更具体地，本发明提供了治疗与IKK2相关的各种疾病的方法，包括治疗炎症、其他与炎症相关的疾病，如作为镇痛剂治疗疼痛和头痛、关节炎，包括但不限于类风湿关节炎、哮喘、胃肠疾病如炎症性肠病、血管疾病、病毒感染如艾滋病和癌症。
• [EN] BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY<br/>[FR] DERIVES DE BENZOPYRANE ET BENZOTHYOPYRANE PRESENTANT UNE ACTIVITE RETINOÏDE DE TYPE ANTAGONISTE
  申请人：ALLERGAN SALES, INC.

  公开号：WO1999033821A1

  公开（公告）日：1999-07-08

  (EN) 2,2-Dialkyl- 4-aryl-substituted benzopyran and benzothiopyran derivatives of formula (I) where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action or RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.(FR) L'invention concerne des dérivés de 2,2-dialkyl-benzopyrane et benzothiopyrane à substitution 4-aryl de formule (I), dont les symboles sont définis dans le descriptif. Ces dérivés présentent des activités biologiques rétinoïdes de type antagonistes et/ou hormones négatives. Les antagonistes de RAR de l'invention peuvent être administrés aux mammifères, y compris aux humains, pour prévenir ou réduire l'action d'antagonistes de RAR sur les sites récepteurs liés. En particulier, les agonistes de RAR sont administrés ou co-administrés avec des médicaments rétinoïdes pour empêcher ou atténuer la toxicité ou les effets secondaires des rétinoïdes, de la vitamine A ou des précurseurs de la vitamine A. Les hormones négatives rétinoïdes peuvent être utilisées pour renforcer les activités d'autres rétinoïdes et celles d'agonistes de récepteurs nucléaires.

  2,2-二烷基-4-芳基取代苯并吡喃和苯并噻吩的衍生物，其化学式为(I)，其中符号的含义在说明书中描述，具有视黄醇负性激素和/或拮抗剂样生物活性。发明的RAR拮抗剂可用于哺乳动物，包括人类，以防止或减少RAR激动剂对结合受体位点的作用。具体而言，RAR激动剂与视黄醇药物一起给予或联合给予，以防止或缓解视黄醇或维生素A或维生素A前体引起的毒性或副作用。视黄醇负性激素可用于增强其他视黄醇和核受体激动剂的活性。
• Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
  申请人：——

  公开号：US20020173631A1

  公开（公告）日：2002-11-21

  Compounds of the formula 1 where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

  式子1中的符号所描述的化合物具有类视黄醇或类视黄醇拮抗剂类似的生物活性。